Biotech Values

[DewDiligence]

I'm not referring to either of them having access to the double-blinded results, rather I think they had enough in house testing/knowledge that they were likely to suspect that Lucentis might perform significantly better.

Thanks for the clarification. I agree that Roche and NVS may have in-house info on the safety advantage of Lucentis apart from what has been found in the Hopkins/Medicare study. If they do have such information, they may be holding it for a tactical release to coincide with the reporting of data from the NIH CATT study.